Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Connor Johnson

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Current Oncology Reports|January 21, 2022
Engineered T Cells: CAR T Cell Therapy and BeyondP Connor Johnson, Jeremy S Abramson
Oncology (Williston Park, N.Y.)|August 24, 2022
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP Connor Johnson, Jeremy S Abramson
Leukemia & Lymphoma|July 3, 2020
Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomasP Connor Johnson, Jeremy S Abramson
Proceedings (Baylor University. Medical Center)|October 2, 2015
A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitisP Connor Johnson, Muthiah Vaduganathan, Kristy M Phillips, et al.
Clinical and Translational Radiation Oncology|August 26, 2024
Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case reportHazim S Ababneh, P Connor Johnson, Jennifer Pursley, et al.
Cancer|April 7, 2026
Beyond age: Frailty-guided care in hematologic malignanciesReed Friend, P Connor Johnson, Daphne Campbell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 11, 2022
Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapyHazim S Ababneh, Jeremy S Abramson, P Connor Johnson, et al.
Biochemical and Biophysical Research Communications|July 27, 2010
The MAP kinase Pmk1 and protein kinase A are required for rotenone resistance in the fission yeast, Schizosaccharomyces pombeYiwei Wang, Galina Gulis, Scott Buckner, et al.
Transplantation and Cellular Therapy|February 27, 2024
Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell TherapyP Connor Johnson, Isabel Neckermann, Hossein Sadrzadeh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2026
Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignanciesHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Current Oncology Reports|January 21, 2022
Engineered T Cells: CAR T Cell Therapy and BeyondP Connor Johnson, Jeremy S Abramson
Oncology (Williston Park, N.Y.)|August 24, 2022
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP Connor Johnson, Jeremy S Abramson
Leukemia & Lymphoma|July 3, 2020
Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomasP Connor Johnson, Jeremy S Abramson
Proceedings (Baylor University. Medical Center)|October 2, 2015
A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitisP Connor Johnson, Muthiah Vaduganathan, Kristy M Phillips, et al.
Clinical and Translational Radiation Oncology|August 26, 2024
Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case reportHazim S Ababneh, P Connor Johnson, Jennifer Pursley, et al.
Cancer|April 7, 2026
Beyond age: Frailty-guided care in hematologic malignanciesReed Friend, P Connor Johnson, Daphne Campbell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 11, 2022
Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapyHazim S Ababneh, Jeremy S Abramson, P Connor Johnson, et al.
Biochemical and Biophysical Research Communications|July 27, 2010
The MAP kinase Pmk1 and protein kinase A are required for rotenone resistance in the fission yeast, Schizosaccharomyces pombeYiwei Wang, Galina Gulis, Scott Buckner, et al.
Transplantation and Cellular Therapy|February 27, 2024
Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell TherapyP Connor Johnson, Isabel Neckermann, Hossein Sadrzadeh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2026
Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignanciesHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Pageof 6